DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition

• Published in: The international journal of biochemistry & cell biology 2023-11, Vol.164, p.106477-106477, Article 106477
• Main Authors: Brooksbank, Kirsten, Martin, Sarah A.
• Format: Article
• Language: English
• ISSN: 1357-2725; 1878-5875
• DOI: 10.1016/j.biocel.2023.106477

The DNA mismatch repair pathway is involved in the identification, excision, and repair of base-base mismatches and indel loops in the genome. Mismatch repair deficiency occurs in approximately 20% of all cancers and results in a type of DNA damage called microsatellite instability. In 2017, the immune checkpoint inhibitor, Pembrolizumab, an anti-PD-1 therapy, was approved for use in all unresectable or metastatic tumours that were mismatch repair deficient or had high microsatellite instability regardless of tissue origin. This landmark approval was the first time a drug had been approved in a site agnostic way, but accumulating data has revealed that up to 50% of mismatch repair deficient tumours are refractory to treatment and there is a huge amount of variability in the therapeutic benefit amongst responders. Several mechanisms of resistance to immune checkpoint blockade for mismatch repair deficient cancers have been identified but our understanding of what is driving resistance in a proportion of patients remains lacking. In this review article, we discuss the emerging mechanisms of resistance which may enable optimal stratification of patients for treatment with immune checkpoint inhibitors in the future.